Price for Spark gene therapy too high, ICER says – BioPharma Dive
Philadelphia Business Journal |
Price for Spark gene therapy too high, ICER says
BioPharma Dive Spark Therapeutics Inc.'s newly approved gene therapy for a rare form of blindness is too expensive to be considered cost-effective, according to a new report from a research organization known for its critiques of industry pricing practices. Currently … Nonprofit agency says Spark's gene therapy $425K price tag is too high ICER report critical of Spark Therapeutics' pricing of Luxturna |
